HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $28 Price Target

Benzinga · 10/16 18:41
HC Wainwright & Co. analyst Edward White reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $28 price target.